Chugai to sell C&C Research Laboratories stake to JW Pharmaceutical
Category: #health  By Mateen Dalal  Date: 2019-11-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Chugai to sell C&C Research Laboratories stake to JW Pharmaceutical

Japan’s research-based pharma company, Chugai Pharmaceutical Co., Ltd. has recently made it to headlines when it agreed to change the equity structure of C&C Research Laboratories (C&C), a Korean joint venture which it formed with JW Pharmaceutical Corp.

According to reliable sources, Chugai would sell its C&C’s share to JWP by the end of this year. This would make C&C a fully owned subsidiary of JWP and would allow it to continue its research in drug discovery with independent management.

Reportedly, the move comes after both the firms agree that C&C has flourished to advance its drug candidates such as gout treatment and atopic dermatitis, and is quite capable of organizing its research programs as an independent entity. Both Chugai and JWP will maintain cordial partnerships and favorably collaborate on C&C’s latest drug candidates.

Speaking on the move, Tatsuro Kosaka, President and CEO, Chugai, said that C&C has developed numerous drug candidates which have entered the clinical study stage. The company has also attained the initial goal of creating a novel drug discovery base with superior technological abilities in Korea.

Kosaka added that Chugai values JWP’s partnership and is looking forward to seeing several ground-breaking innovations from C&C in the forthcoming years.

As per Young sub Shin, CEO, JWP, C&C has developed synergy by integrating Korea’s human infrastructure with Chugai’s knowledge on latest drug development. The company is thankful for Chugai’s continuous support ever since its inception and will work hard on growing C&C as an international R&D venture.

Prior to this news, Chugai had revealed that its “Annual Report 2018” had bagged an award in the 7th WICI Japan Award for Excellence in Integrated Reporting. Reportedly, this is the first award that the company has received from WICI Japan, which was for “the Prize for Excellence in Integrated Reporting”.

Sources cite that Chugai’s annual report was acclaimed as an outstanding example of integrated reporting with a superior level of thoroughness that grants an insightful view of the firm’s future.

Source Credit: https://www.chugai-pharm.co.jp/english/news/detail/20191127160000_672.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
By Mateen Dalal

Mercedes-AMG Petronas F1 Team, and Advanced Micro Devices (AMD), a renowned semiconductor developer, have reportedly announced a new multi-year partnership agreement that has combined the two firms’ passion of for high performance, beginning fr...

Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
By Mateen Dalal

The biopharmaceutical giant has also received a USD 10 million development milestone payment from Merck & CO. for the initiation of the trial A clinical-stage biopharmaceutical company, Aduro Biotech, Inc. recently announced to have ba...

TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
By Mateen Dalal

TherapeuticsMD, Inc., an inventive pharmaceutical company that focuses on women healthcare, has recently announced that it has presented a New Drug Application (NDA) pre-approval efficacy supplement to the U.S. FDA (Food and Drug Administration) for ...